Continuing Medical Education Program – Purchase Activities

The purpose of The Medical Letter Continuing Medical Education Program is to provide a means for healthcare professionals (including physicians, physician assistants, nurse practitioners, and pharmacists) to keep up to date with new drugs and changes in therapeutics. The objectives of the program are to educate the participants, impact clinical practice, and improve patient outcomes. The Medical Letter CME Program is funded by fees paid by the activity participants. The Medical Letter is free of commercial influence and financial sponsorship.

The Medical Letter Individual Activities — Online Only

I would like to order the following Per Issue Activities eligible for 2 credits each:

$15 per activity
3 or more: $10/activity

	1648 (2 credits) Expires 04/06/2023 In Brief: Expanded Heart Failure Indication for Empagliflozin (Jardiance) Tramadol/Celecoxib (Seglentis) for Pain A Drug-Eluting Contact Lens for Allergic Conjunctivitis Zimhi - A Higher-Dose Injectable Naloxone for Opioid Overdose Efgartigimod alfa (Vyvgart) for Myasthenia Gravis

	1649 (2 credits) Expires 04/20/2023 Drugs for Benign Prostatic Hyperplasia Vazalore - A New Aspirin Formulation A Ranibizumab Ocular Implant (Susvimo) for Age-Related Macular Degeneration

	1650 (2 credits) A Three-Antigen Hepatitis B Vaccine (PreHevbrio) Tretinoin/Benzoyl Peroxide Cream (Twyneo) for Acne Delayed-Release Budesonide (Tarpeyo) for Primary Immunoglobulin A Nephropathy OTC Alcaftadine (Lastacaft Once Daily Relief) for Allergic Conjunctivitis Higher-Dose Semaglutide (Ozempic) for Type 2 Diabetes

	1651 (2 credits) Drugs and Devices for Weight Management

	1652 (2 credits) Mavacamten (Camzyos) for Obstructive Hypertrophic Cardiomyopathy Tenapanor (Ibsrela) for Irritable Bowel Syndrome with Constipation

	1653 (2 credits) Drugs for Sexually Transmitted Infections

	1654 (2 credits) Tirzepatide (Mounjaro) for Type 2 Diabetes Daridorexant (Quviviq) for Insomnia COVID-19 Updates

	1655 (2 credits) Drugs for Treatment and Prevention of Venous Thromboembolism

	1656 (2 credits) COVID-19 Updates Tapinarof Cream (Vtama) for Psoriasis Oteseconazole (Vivjoa) for Recurrent Vulvovaginal Candidiasis Lumateperone (Caplyta) for Bipolar Depression

	1657 (2 credits) Drugs for Cognitive Loss and Dementia

	1658 (2 credits) Prevention and Treatment of Monkeypox Baricitinib (Olumiant) for Severe Alopecia Areata Nalmefene Returns for Reversal of Opioid Overdose Upadacitinib (Rinvoq): A Second JAK Inhibitor for Ulcerative Colitis

	1659 (2 credits) Lipid-Lowering Drugs

	1660 (2 credits) Influenza Vaccine for 2022-2023 Ruxolitinib Cream (Opzelura) for Nonsegmental Vitiligo COVID-19 Update

	1661 (2 credits) Adult Immunization

	1662 (2 credits) Two Vonoprazan Combinations (Voquezna) for H. pylori Two New Oral Testosterone Products for Hypogonadism Phosphodiesterase-5 Inhibitors for Alzheimer's Disease? OTC Azelastine Nasal Spray 0.15% (Astepro Allergy) for Allergic Rhinitis

	1663 (2 credits) Drugs for Type 2 Diabetes

	1664 (2 credits) Antiviral Drugs for Influenza for 2022-2023 Relyvrio for ALS Alternatives to Adderall

	1665 (2 credits) Opioids for Pain

	1666 (2 credits) Dextromethorphan/Bupropion (Auvelity) for Depression Dexmedetomidine Sublingual Film (Igalmi) for Acute Agitation Risankizumab (Skyrizi) - An IL-23 Antagonist for Crohn's Disease Oral Minoxidil for Hair Loss

	1667 (2 credits) Drugs for Chronic Insomnia Teplizumab (Tzield) to Delay Onset of Type 1 Diabetes

	1668 (2 credits) Hemgenix - A Gene Therapy for Hemophilia B Topical Roflumilast (Zoryve) for Plaque Psoriasis Olopatadine/Mometasone (Ryaltris) for Allergic Rhinitis Furoscix - A Subcutaneous Furosemide Infusor for Heart Failure Finerenone (Kerendia) for Diabetic Kidney Disease

	1669 (2 credits) Lecanemab (Leqembi) for Alzheimer's Disease Dupilumab (Dupixent) for Eosinophilic Esophagitis and Prurigo Nodularis Epsolay - A Benzoyl Peroxide Cream for Rosacea Transdermal Dextroamphetamine (Xelstrym) for ADHD

	1670 (2 credits) Drugs for Hypothyroidism Deucravacitinib (Sotyktu) for Plaque Psoriasis Expanded Access to Mifepristone Semaglutide (Wegovy) for Weight Loss in Children

	1671 (2 credits) Antiviral Drugs for COVID-19 in Vaccinated Outpatients Live Fecal Microbiota (Rebyota) for Prevention of CDI Recurrence Ublituximab (Briumvi) for Relapsing Multiple Sclerosis Elacestrant (Orserdu) for Advanced or Metastatic Breast Cancer

	1672 (2 credits) Drugs for Overactive Bladder A Dexamethasone Ophthalmic Insert (Dextenza) for Allergic Conjunctivitis Terlipressin (Terlivaz) for Hepatorenal Syndrome Off-Label Amitriptyline for Insomnia

	1673 (2 credits) Pegcetacoplan (Syfovre) for Geographic Atrophy in Age-Related Macular Degeneration Three Drugs for Atopic Dermatitis

Add to Cart

ACCME The Medical Letter is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Medical Letter Inc. designates this enduring material for a maximum of 2 AMA PRA Category 1 Credit(s)^TM.

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Your participation information will be shared with ABIM through PARS.

AAFP The AAFP has reviewed The Medical Letter Continuing Education Program, and deemed it acceptable for AAFP credit. Term of approval is from 01/01/2023 to 12/31/2023. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA This activity has been reviewed by the AAPA Review Panel and is compliant with AAPA CME Criteria. PAs should only claim credit commensurate with the extent of their participation.

Accreditation Council on Pharmacy Education
The Medical Letter is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Each exam is acceptable for 2.0 hours of knowledge-based continuing education credit (0.2 CEU).